

1204

+3012584620

T-923 P.01

Job-241

J. Timothy Meigs  
Sector Patent Counsel

Genetic Therapy, Inc.  
9 West Watkins Mill Road  
Gaithersburg, MD 20878

Tel (301) 258-4715  
Fax (301) 258-4620  
Email: tim.meigs@pharma.novartis.com

#399

11/27/02

(NE)



**GENETIC THERAPY, INC.**  
A Novartis Company

Fax

**FAX RECEIVED**

NOV 27 2002

**GROUP 1600**

Attention Examiner Ram R. Shukla, PTO Art Unit 1632

Fax no. (703) 308-4242

Number of  
pages 7

Date Nov. 26, 2002

CONFIDENTIAL

RE: 08/704,445

Dear Examiner Shukla,

Please enter the attached amendment in application no. 08/704,445.

Respectfully submitted,

J. Timothy Meigs  
Attorney for Applicant  
Reg. No. 38,241

**PRIVILEGED AND CONFIDENTIAL** information intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and return the original to us at the address above via the U.S. Mail. Thank you.

NOVARTIS

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the  
Patent Office Fax No. (703) 308-4242 on the date shown below.

J. Timothy Meigs      J. Timothy Meigs      11/26/02  
Type or Print Name      Signature      Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

**Chen et al.**

Art Unit: 1632

Serial No. 08/704,445

Examiner: Shukla, Ram R.

Filed: August 26, 1996

Atty Docket: 4-127-1000P1/CONT/SYS

For: **Methods For Preventing Depletion** :  
**Of Non-Autologous Hematopoietic** :  
**Cells and Animal Model Systems** :  
**for Use Thereof** :

Confirmation No. 9201

**AMENDMENT AND RESPONSE**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Responsive to the Office Action of August 27, 2002 (Paper No. 38), Applicant respectfully requests reconsideration of the above-identified application in view of the following amendments and remarks.

It is believed that no extensions of time are necessary. However, if one is deemed necessary to maintain pendency of this application, the Commissioner is authorized to charge any fees under 37 C.F.R. §1.17 that may be required, or credit any overpayment, to Applicant's deposit account no. 19-0134.